Malignant mesothelioma
-
* Corresponding author: Alastair J Moore a.moore@ic.ac.uk
Orphanet Journal of Rare Diseases 2008, 3:34 doi:10.1186/1750-1172-3-34
1 cm and 4) mediastinal pleural involvement. Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care. Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis." /> 1 cm and 4) mediastinal pleural involvement. Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care. Compensation issues must also be considered. Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis." />
* Corresponding author: Alastair J Moore a.moore@ic.ac.uk
Orphanet Journal of Rare Diseases 2008, 3:34 doi:10.1186/1750-1172-3-34